Corvus Pharmaceuticals (CRVS) PT Raised to $13 at Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CRVS Hot Sheet
Price: $10.03 --0%
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Join SI Premium – FREE
Mizuho analyst Graig Suvannavejh raised the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $13.00 (from $11.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Corvus Pharmaceuticals (CRVS) PT Lowered to $27 at Mizuho
- World Kinect (WKC) PT Lowered to $39 at BofA Securities
- Macquarie Upgrades Manila Electric Co. (MER:PM) (MAEOY) to Outperform
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
